Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.

[1]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[2]  Brian M. Owens.  Kinesin inhibitor marches toward first-in-class pivotal trial , 2013, Nature Medicine.

[3]  A. Heijink,et al.  Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination , 2013, Oncogene.

[4]  H. B. El-Nassan,et al.  Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. , 2013, European journal of medicinal chemistry.

[5]  O. Rath,et al.  Structural insights into a unique inhibitor binding pocket in kinesin spindle protein. , 2013, Journal of the American Chemical Society.

[6]  P. Albers,et al.  Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer , 2013, Investigational New Drugs.

[7]  S. Lonial,et al.  ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study , 2011 .

[8]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[9]  Suzanne F. Jones,et al.  A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors , 2011, Investigational New Drugs.

[10]  J. Richard,et al.  Allosteric Drug Discrimination Is Coupled to Mechanochemical Changes in the Kinesin-5 Motor Core* , 2010, The Journal of Biological Chemistry.

[11]  K. Anderson,et al.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.

[12]  W. Kuo,et al.  Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer , 2010, Clinical Cancer Research.

[13]  B. Tunquist,et al.  ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. , 2009, Anticancer Research.

[14]  Hirdesh Uppal,et al.  In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. , 2009, Toxicology letters.

[15]  B. Teicher,et al.  Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs. , 2009, International journal of oncology.

[16]  B. Teicher,et al.  Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents , 2009, Cancer Chemotherapy and Pharmacology.

[17]  A. Rath,et al.  Detergent binding explains anomalous SDS-PAGE migration of membrane proteins , 2009, Proceedings of the National Academy of Sciences.

[18]  A. Merdes,et al.  Spindle assembly defects leading to the formation of a monopolar mitotic apparatus , 2009, Biology of the cell.

[19]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Tsao,et al.  Id1 overexpression induces tetraploidization and multiple abnormal mitotic phenotypes by modulating aurora A. , 2008, Molecular biology of the cell.

[21]  W. Dalton,et al.  The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.

[22]  Stuart L Schreiber,et al.  Towards the optimal screening collection: a synthesis strategy. , 2008, Angewandte Chemie.

[23]  Latesh Lad,et al.  Mechanism of inhibition of human KSP by ispinesib. , 2008, Biochemistry.

[24]  Neysa Nevins,et al.  ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. , 2007, Nature chemical biology.

[25]  Makoto Kinoshita,et al.  [Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[26]  R. Wäsch,et al.  Characterization of in vitro growth of multiple myeloma cells. , 2007, Experimental hematology.

[27]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[28]  E. Salmon,et al.  The spindle-assembly checkpoint in space and time , 2007, Nature Reviews Molecular Cell Biology.

[29]  W. Dalton,et al.  Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma , 2006, Clinical Cancer Research.

[30]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[31]  Hongmao Sun,et al.  Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Rafii,et al.  Osteopetrotic mouse stroma with thrombopoietin, c-kit ligand, and flk-2 ligand supports long-term mobilized CD34+ hematopoiesis in vitro. , 2005, Stem cells and development.

[33]  R. Copeland,et al.  Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition. , 2004, Biochemistry.

[34]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[35]  D Parent-Massin,et al.  Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  B. Dörken,et al.  In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. , 2002, Blood.

[37]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[38]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[39]  K. Orita,et al.  Human bone marrow stroma‐dependent cell line MOLP‐5 derived from a patient in leukaemic phase of multiple myeloma , 2000, British journal of haematology.

[40]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[41]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[42]  M. Ghielmini,et al.  Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  L. Dick,et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. , 1998, Bioorganic & medicinal chemistry letters.

[44]  T. Facon,et al.  MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL , 1996, British journal of haematology.

[45]  H. Lane,et al.  Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo , 1995, Cell.

[46]  R F Standaert,et al.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin , 1995, Science.

[47]  M. Dimopoulos,et al.  Primary therapy of multiple myeloma with paclitaxel (taxol). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Salmon Se,et al.  Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. , 1975 .

[49]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[50]  M. Gordon.  Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma , 2006 .

[51]  R. Parchment,et al.  Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro , 1997, Cancer Chemotherapy and Pharmacology.

[52]  D. Alberts,et al.  Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. , 1975, Cancer chemotherapy reports.

[53]  A. W. Schüttelkopf,et al.  Biological Crystallography the Structure of the Ternary Eg5–adp–ispinesib Complex , 2022 .